GoodRx Holdings (NASDAQ:GDRX) Full Year 2024 Results

Key Financial Results

• Revenue: US$792.3m (up 5.6% from FY 2023).
• Net income: US$16.4m (up from US$8.87m loss in FY 2023).
• Profit margin: 2.1% (up from net loss in FY 2023).
• EPS: US$0.042 (up from US$0.022 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

GoodRx Holdings EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 46%.

Looking ahead, revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Healthcare Services industry in the US.

The company's shares are up 3.5% from a week ago.

Risk Analysis

Don't forget that there may still be risks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.